Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular ...
Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease
Source: eagletribune.com